Form 4: Apogee Therapeutics CEO Granted Stock Options

Apogee Therapeutics CEO, Michael Henderson, was granted stock options for 357,036 shares, vesting over four years.

Summary

• Apogee Therapeutics granted their Chief Executive Officer, Michael Henderson, stock options to purchase 357,036 shares of common stock.
• The options were granted on December 9, 2024, at an exercise price of $49.07 per share.
• The options will vest in 48 equal monthly installments over a four-year period, contingent on Mr. Henderson's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally positive for aligning management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The value of the options is dependent on the future performance of Apogee Therapeutics' stock price.
• If the CEO leaves the company before the options fully vest, he may forfeit some or all of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain top talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Regeneron, Amgen, and Biogen.
• The vesting schedule of four years is also typical, aligning with long-term value creation.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity compensation, CEO, Apogee Therapeutics, vesting, common stock